USFDA also approved complementary diagnostic imaging agent, Locametz, after radiolabeling with gallium-68 for the identification of PSMA-positive lesions
Paige Breast Lymph Node designed to enhance diagnostic accuracy and confidence detecting breast cancer metastases of any size in lymph node tissue
The approval is based on new data from cohorts D and K of the KEYNOTE-158 trial
In a Nature Communications Medicine publication, the Verita proprietary platform detected 96 per cent of stage 1 pancreatic cancers and three-quarters of stage 1 ovarian cancers using isolated exosomes and AI-enabled protein marker analysis
At the interim analysis, the combination of Keytruda and Lynparza did not demonstrate a benefit in overall survival (OS), one of the study’s dual primary endpoints, compared to the control arm of either abiraterone acetate or enzalutamide
First PARP inhibitor to demonstrate overall survival benefit in early breast cancer
According to the Indian Council of Medical Research (ICMR), there will be an estimated 12 % rise in cancer cases in India in the next five years
Onco Care Plus is available at just INR 399 per month, and provides services like free doctor consultation, 15% off on cancer treatment costs, 25% off for diagnostic tests, free nutrition plans, among many more
The single in vitro diagnostic test helps inform therapy decisions according to clinical guidelines to enable precision medicine earlier in the disease journey
Lynparza is approved in the US, EU, Japan and several other countries for the treatment of patients with gBRCAm, HER2-negative, metastatic breast cancer previously treated with chemotherapy based on results from the OlympiAD Phase III trial
Subscribe To Our Newsletter & Stay Updated
